Eli Lilly Shares Tumble After Disappointing Q3 Earnings Report.
Eli Lilly (LLY) experienced a significant decline in its stock price following the release of its third-quarter earnings report, which fell short of Wall Street expectations. Shares dropped as much as 10% in premarket trading after the pharmaceutical giant reported revenues of $11.4 billion, below analysts’ forecasts of $12.17 billion, despite reflecting a robust 20% year-over-year growth.
The company's reported profit of $970.3 million also did not meet expectations, prompting Eli Lilly to revise its profit guidance and adjust its revenue forecast for the year.
Key Highlights from the Earnings Report
A central aspect of Eli Lilly’s performance revolves around its GLP-1 portfolio, which includes the popular weight-loss medication Zepbound and the diabetes treatment Mounjaro. Although Mounjaro contributed significantly to the revenue, the performance of Zepbound was underwhelming; it generated approximately $1.3 billion in sales, falling short of the $1.7 billion expected by analysts.
Sales for both medications were negatively impacted by inventory reductions within the wholesaler channel, leading to concerns about future growth potential.
Analyst Insights
Jared Holz, a healthcare analyst at Mizuho, commented on the earnings, noting that while Zepbound's sales might exceed expectations, Mounjaro could struggle to meet the projected $3.8 billion as more patients shift to Zepbound for its superior weight-loss benefits at higher dosages.
Jared Holz observed that investors are cautious, stating: "Some have asserted that the stock and group have peaked. Given the complexities around much of the healthcare sector and difficulty establishing a simple thesis for the vast majority of names in Pharma/Biotech or otherwise, we think investors will remain very engaged in weight-loss names."
Broader Market Implications
Despite the earnings setback, Eli Lilly remains a key player in the pharmaceutical industry, with aspirations extending beyond the GLP-1 market. The company is also advancing a candidate for Alzheimer's treatment that may rival Biogen’s Leqembi. A recent study suggests that using lower initial doses could mitigate the risk of brain swelling—a common side effect associated with Alzheimer’s medications, including Lilly’s Kisunla.
The burgeoning market for obesity treatments has driven significant stock growth for Eli Lilly in recent years, with the company positioning itself to potentially become the first trillion-dollar entity in the healthcare sector. Since the start of 2024, its stock has surged over 50%.
Future Directions
To mitigate medication shortages, particularly for tirzepatide-containing drugs, Eli Lilly has made considerable efforts, including the introduction of a direct-to-consumer platform. This allows cash-paying patients to purchase vials of medication at reduced prices, a shift from traditional auto-injector pens.
Eli Lilly and Co (Lilly) is a prominent healthcare company dedicated to discovering, developing, and marketing a variety of human healthcare products. The company provides medications for conditions such as cardiovascular diseases, diabetes, endocrinology, cancer, neurological disorders, autoimmune diseases, men's health, and musculoskeletal issues. Lilly distributes its pharmaceutical products through independent wholesale distributors, leveraging the power of biotechnology, chemistry, and genetic medicine to enhance patient care.
Related: Vaxart’s $40 Million Common Stock Offering
